Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1854 1
1891 1
1897 1
1907 1
1908 1
1909 1
1910 1
1911 1
1914 1
1924 1
1930 1
1945 2
1946 1
1947 2
1950 1
1951 3
1952 6
1953 3
1954 1
1955 2
1956 3
1957 4
1958 5
1959 8
1961 2
1962 2
1963 1
1964 3
1965 6
1966 8
1967 7
1968 4
1969 10
1970 12
1971 10
1972 8
1973 2
1974 7
1975 9
1976 7
1977 6
1978 10
1979 18
1980 9
1981 5
1982 12
1983 11
1984 11
1985 13
1986 13
1987 16
1988 10
1989 11
1990 21
1991 21
1992 17
1993 24
1994 24
1995 25
1996 19
1997 21
1998 18
1999 23
2000 21
2001 19
2002 33
2003 22
2004 35
2005 45
2006 44
2007 51
2008 34
2009 22
2010 35
2011 43
2012 55
2013 61
2014 67
2015 71
2016 77
2017 64
2018 86
2019 112
2020 115
2021 109
2022 103
2023 125
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

1,830 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial.
Lafayette R, Kristensen J, Stone A, Floege J, Tesař V, Trimarchi H, Zhang H, Eren N, Paliege A, Reich HN, Rovin BH, Barratt J; NefIgArd trial investigators. Lafayette R, et al. Among authors: stone a. Lancet. 2023 Sep 9;402(10405):859-870. doi: 10.1016/S0140-6736(23)01554-4. Epub 2023 Aug 14. Lancet. 2023. PMID: 37591292 Clinical Trial.
Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy.
Barratt J, Lafayette R, Kristensen J, Stone A, Cattran D, Floege J, Tesar V, Trimarchi H, Zhang H, Eren N, Paliege A, Rovin BH; NefIgArd Trial Investigators. Barratt J, et al. Among authors: stone a. Kidney Int. 2023 Feb;103(2):391-402. doi: 10.1016/j.kint.2022.09.017. Epub 2022 Oct 19. Kidney Int. 2023. PMID: 36270561 Free article. Clinical Trial.
Human Bone Marrow Organoids for Disease Modeling, Discovery, and Validation of Therapeutic Targets in Hematologic Malignancies.
Khan AO, Rodriguez-Romera A, Reyat JS, Olijnik AA, Colombo M, Wang G, Wen WX, Sousos N, Murphy LC, Grygielska B, Perrella G, Mahony CB, Ling RE, Elliott NE, Karali CS, Stone AP, Kemble S, Cutler EA, Fielding AK, Croft AP, Bassett D, Poologasundarampillai G, Roy A, Gooding S, Rayes J, Machlus KR, Psaila B. Khan AO, et al. Among authors: stone ap. Cancer Discov. 2023 Feb 6;13(2):364-385. doi: 10.1158/2159-8290.CD-22-0199. Cancer Discov. 2023. PMID: 36351055 Free PMC article.
Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial.
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, Kranzler HR, Gelernter J, Pyne JM, Stone A, DuVall SL, Lehmann LS, Thase ME; PRIME Care Research Group; Aslam M, Batki SL, Bjork JM, Blow FC, Brenner LA, Chen P, Desai S, Dieperink EW, Fears SC, Fuller MA, Goodman CS, Graham DP, Haas GL, Hamner MB, Helstrom AW, Hurley RA, Icardi MS, Jurjus GJ, Kilbourne AM, Kreyenbuhl J, Lache DJ, Lieske SP, Lynch JA, Meyer LJ, Montalvo C, Muralidhar S, Ostacher MJ, Paschall GY, Pfeiffer PN, Prieto S, Przygodzki RM, Ranganathan M, Rodriguez-Suarez MM, Roggenkamp H, Schichman SA, Schneeweis JS, Simonetti JA, Steinhauer SR, Suppes T, Umbert MA, Vassy JL, Voora D, Wiechers IR, Wood AE. Oslin DW, et al. Among authors: stone a. JAMA. 2022 Jul 12;328(2):151-161. doi: 10.1001/jama.2022.9805. JAMA. 2022. PMID: 35819423 Free PMC article. Clinical Trial.
Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study.
Meric-Bernstam F, Hurwitz H, Raghav KPS, McWilliams RR, Fakih M, VanderWalde A, Swanton C, Kurzrock R, Burris H, Sweeney C, Bose R, Spigel DR, Beattie MS, Blotner S, Stone A, Schulze K, Cuchelkar V, Hainsworth J. Meric-Bernstam F, et al. Among authors: stone a. Lancet Oncol. 2019 Apr;20(4):518-530. doi: 10.1016/S1470-2045(18)30904-5. Epub 2019 Mar 8. Lancet Oncol. 2019. PMID: 30857956 Free PMC article. Clinical Trial.
Feminization Rhinoplasty.
Flaherty AJ, Stone AM, Teixeira JC, Nuara MJ. Flaherty AJ, et al. Among authors: stone am. Facial Plast Surg Clin North Am. 2023 Aug;31(3):407-417. doi: 10.1016/j.fsc.2023.04.005. Facial Plast Surg Clin North Am. 2023. PMID: 37348984 Review.
Data privacy: a decade of confusion.
Stone A, Carrigan C. Stone A, et al. BMJ. 2023 Mar 9;380:520. doi: 10.1136/bmj.p520. BMJ. 2023. PMID: 36894177 No abstract available.
1,830 results